Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs PayPal Holdings, Inc. (PYPL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs PayPal Holdings, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.96 (market cap $29.60B), while PayPal Holdings, Inc. trades at $58.31 (market cap $50.47B). The key difference: PayPal Holdings, Inc. is the larger of the two by market cap, and PayPal Holdings, Inc. pays a 0.95% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | PYPL | |
|---|---|---|
Market Cap | $29.60B | $50.47B |
Sector | Health | Financials |
52-Week High | $491.22 | $76.13 |
52-Week Low | $205.48 | $39.08 |
Enterprise Value | $27.56B | $52.62B |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
PayPal trades at $59.07, showing stability with no recent price change. The stock exhibits bullish technical signals with strong moving average support and trades near key resistance at $60. Fundamentally, PayPal delivered Q2 2026 earnings beat with $1.38 EPS versus $1.28 expected, while revenue grew to $33.17 billion in 2025 with improving profit margins. Recent news highlights acquisition interest and strategic partnerships expanding payment capabilities.
PayPal presents a compelling value opportunity with attractive valuation multiples (P/E 11.15, P/S 1.6) and strong cash flow generation ($6.42B operating cash flow). However, risks include competitive pressures in digital payments and execution challenges under new leadership. Analyst consensus leans neutral with 60% hold ratings, though the $58.75 price target suggests limited upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About PayPal Holdings, Inc.
PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →
